Increased Adrenocortical and Adrenomedullary Function in Rats Treated With Hyperbaric Oxygenation

Nakada, Teruhiro; Yoshikawa, Munehide; Katayama, Takashi; Saito, Haruo; Ota, Kokichi; Chikenji, Masaru; Matsushita, Noriyoshi

doi:10.5980/jpnjurol1928.75.3_490

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It also constricts the lung passages and damages the secretion of mucus in the lungs. Boswellic acids and B. serrata extract have unique character owing to the dual inhibition of 5-lipoxygenase and HLE (Safayhi et al 1997 ; Siddiqui 2011 ; Zhang et al 2019 ; Roy et al 2019 ). In a recent study, Gilbert et al ( 2020 ) investigated the precise effect of B. serrata extract on the production of leukotienes, inflammatory mediators associated with asthma, by studying the structural changes and molecular mechanism of 5-lipoxygenase inhibition by AKBA.…”

Section: Potential Therapeutic Effects Of Boswellic Acids/ B Serrata Extract Against Sars-cov-2-induced Pulmonary Lesimentioning

confidence: 99%

“…Gum resin extract of Boswellia serrata ( B. serrata ) has been used for centuries to treat a wide range of inflammatory diseases such as arthritis, diabetes, asthma, cancer, or inflammatory bowel (Roy et al 2019 ). Zang et al ( 2019 ) confirmed that the anti-inflammatory effect of B. serrata could be a potential therapy for the treatment of several inflammatory diseases. Phytochemical examination by thin-layer chromatography showed the main components present in the gum resin of B. serrata included terpenoids, phenolic compounds, flavonoids, and phenylpropanoids (Ayub et al 2018 ).…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly

et al. 2021

View full text Add to dashboard Cite

The most severe cases of COVID-19, and the highest rates of death, are among the elderly. There is an urgent need to search for an agent to treat the disease and control its progression. Boswellia serrata is traditionally used to treat chronic inflammatory diseases of the lung. This review aims to highlight currently published research that has shown evidence of potential therapeutic effects of boswellic acids (BA) and B. serrata extract against COVID-19 and associated conditions. We reviewed the published information up to March 2021. Studies were collected through a search of online electronic databases (academic libraries such as PubMed, Scopus, Web of Science, and Egyptian Knowledge Bank). Several recent studies reported that BAs and B. serrata extract are safe agents and have multiple beneficial activities in treating similar symptoms experienced by patients with COVID-19. Because of the low oral bioavailability and improvement of buccal/oral cavity hygiene, traditional use by chewing B. serrata gum may be more beneficial than oral use. It is the cheapest option for a lot of poorer people. The promising effect of B. serrata and BA can be attributed to its antioxidant, anti-inflammatory, immunomodulatory, cardioprotective, anti-platelet aggregation, antibacterial, antifungal, and broad antiviral activity. B. serrata and BA act by multiple mechanisms. The most common mechanism may be through direct interaction with IκB kinases and inhibiting nuclear factor-κB-regulated gene expression. However, the most recent mechanism proposed that BA not only inhibited the formation of classical 5-lipoxygenase products but also produced anti-inflammatory LOX-isoform-selective modulators. In conclusion a small to moderate dose B. serrata extract may be useful in the enhancing adaptive immune response in mild to moderate symptoms of COVID-19. However, large doses of BA may be beneficial in suppressing uncontrolled activation of the innate immune response. More clinical results are required to determine with certainty whether there is sufficient evidence of the benefits against COVID-19.

show abstract

Section: Potential Therapeutic Effects Of Boswellic Acids/ B Serrata Extract Against Sars-cov-2-induced Pulmonary Lesimentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Several hemodynamic changes are known to occur during and immediately after hyperbaric oxygen exposure [ 7 ], and numerous mechanisms have been suggested to account for this [ 8 , 9 ]. The predominant effect is related to HBOT-induced vasoconstriction, the physiologically protective response to extremely high arterial partial pressures of oxygen [ 7 ], which increases systemic vascular resistance and thus cardiovascular afterload; this is associated with an increase in systolic and mean arterial blood pressure (BP).…”

Section: Introductionmentioning

confidence: 99%

Safety of hyperbaric oxygen therapy in patients with heart failure: A retrospective cohort study

Schiavo,

Brenna,

Albertini

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background Hyperbaric oxygen therapy (HBOT) has several hemodynamic effects including increases in afterload (due to vasoconstriction) and decreases in cardiac output. This, along with rare reports of pulmonary edema during emergency treatment, has led providers to consider HBOT relatively contraindicated in patients with reduced left ventricular ejection fraction (LVEF). However, there is limited evidence regarding the safety of elective HBOT in patients with heart failure (HF), and no existing reports of complications among patients with HF and preserved LVEF. We aimed to retrospectively review patients with preexisting diagnoses of HF who underwent elective HBOT, to analyze HBOT-related acute HF complications. Methods Research Ethics Board approvals were received to retrospectively review patient charts. Patients with a history of HF with either preserved ejection fraction (HFpEF), mid-range ejection fraction (HFmEF), or reduced ejection fraction (HFrEF) who underwent elective HBOT at two Hyperbaric Centers (Toronto General Hospital, Rouge Valley Hyperbaric Medical Centre) between June 2018 and December 2020 were reviewed. Results Twenty-three patients with a history of HF underwent HBOT, completing an average of 39 (range 6–62) consecutive sessions at 2.0 atmospheres absolute (ATA) (n = 11) or at 2.4 ATA (n = 12); only two patients received fewer than 10 sessions. Thirteen patients had HFpEF (mean LVEF 55 ± 7%), and seven patients had HFrEF (mean LVEF 35 ± 8%) as well as concomitantly decreased right ventricle function (n = 5), moderate/severe tricuspid regurgitation (n = 3), or pulmonary hypertension (n = 5). The remaining three patients had HFmEF (mean LVEF 44 ± 4%). All but one patient was receiving fluid balance therapy either with loop diuretics or dialysis. Twenty-one patients completed HBOT without complications. We observed symptoms consistent with HBOT-related HF exacerbation in two patients. One patient with HFrEF (LVEF 24%) developed dyspnea attributed to pulmonary edema after the fourth treatment, and later admitted to voluntarily holding his diuretics before the session. He was managed with increased oral diuretics as an outpatient, and ultimately completed a course of 33 HBOT sessions uneventfully. Another patient with HFpEF (LVEF 64%) developed dyspnea and desaturation after six sessions, requiring hospital admission. Acute coronary ischemia and pulmonary embolism were ruled out, and an elevated BNP and normal LVEF on echocardiogram confirmed a diagnosis of pulmonary edema in the context of HFpEF. Symptoms subsided after diuretic treatment and the patient was discharged home in stable condition, but elected not to resume HBOT. Conclusions Patients with HF, including HFpEF, may develop HF symptoms during HBOT and warrant ongoing surveillance. However, these patients can receive HBOT safely after optimization of HF therapy and fluid restriction.

show abstract

“…Numerous mechanisms for the effect of HBOT on CO have been suggested (13, 14) although this effect predominately results from HBOT-induced vasoconstriction, the physiological protective response to extremely high arterial partial pressures of oxygen (7). These hemodynamic changes appear to be well tolerated in patients without preexisting cardiac disease (15, 16).…”

Section: Introductionmentioning

confidence: 99%

Safety of hyperbaric oxygen therapy in patients with heart failure: A retrospective review

Schiavo,

Brenna,

Albertini

et al. 2023

Preprint

View full text Add to dashboard Cite

BackgroundHyperbaric oxygen therapy (HBOT) has several hemodynamic effects including increases in afterload (due to vasoconstriction) and decreases in cardiac output. This, along with rare reports of pulmonary edema during emergency treatment, has led providers to consider HBOT relatively contraindicated in patients with reduced left ventricular ejection fraction (LVEF). However, there is limited evidence regarding the safety of elective HBOT in patients with heart failure (HF), and no existing reports of complications among patients with HF and preserved LVEF. We aimed to retrospectively review patients with preexisting diagnoses of HF who underwent elective HBOT, to analyze HBOT-related acute HF complications.MethodsResearch Ethics Board approvals were received to retrospectively review patient charts. Patients with a history of HF with either preserved ejection fraction (HFpEF), mid-range ejection fraction (HFmEF), or reduced ejection fraction (HFrEF) who underwent elective HBOT at two Hyperbaric Centers (Toronto General Hospital, Rouge Valley Hyperbaric Medical Centre) between June 2018 and December 2020 were reviewed.ResultsTwenty-three patients with a history of HF underwent HBOT, completing an average of 39 (range 6 – 62) consecutive sessions at 2.0 atmospheres absolute (ATA) (n=11) or at 2.4 ATA (n=12); only two patients received fewer than 10 sessions. Thirteen patients had HFpEF (mean LVEF 55 ± 7%), and seven patients had HFrEF (mean LVEF 35 ± 8%) as well as concomitantly decreased right ventricle function (n=5), moderate/severe tricuspid regurgitation (n=3), or pulmonary hypertension (n=5). The remaining three patients had HFmEF (mean LVEF 44 ± 4%). All but one patient was receiving fluid balance therapy either with loop diuretics or dialysis. Twenty-one patients completed HBOT without complications. We observed symptoms consistent with HBOT-related HF exacerbation in two patients. One patient with HFrEF (LVEF 24%) developed dyspnea attributed to pulmonary edema after the fourth treatment, and later admitted to voluntarily holding his diuretics before the session. He was managed with increased oral diuretics as an outpatient, and ultimately completed a course of 33 HBOT sessions uneventfully. Another patient with HFpEF (LVEF 64%) developed dyspnea and desaturation after six sessions, requiring hospital admission. Acute coronary ischemia and pulmonary embolism were ruled out, and an elevated BNP and normal LVEF on echocardiogram confirmed a diagnosis of pulmonary edema in the context of HFpEF. Symptoms subsided after diuretic treatment and the patient was discharged home in stable condition, but elected not to resume HBOT.ConclusionsPatients with HF, including HFpEF, may develop HF symptoms during HBOT and warrant ongoing surveillance. However, these patients can receive HBOT safely after optimization of HF therapy and fluid restriction.

show abstract

Increased Adrenocortical and Adrenomedullary Function in Rats Treated With Hyperbaric Oxygenation

Cited by 3 publications

References 0 publications

Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly

Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly

Safety of hyperbaric oxygen therapy in patients with heart failure: A retrospective cohort study

Safety of hyperbaric oxygen therapy in patients with heart failure: A retrospective review

Contact Info

Product

Resources

About